HOMB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Home BancShares (HOMB) presents a conflicting profile: it is fundamentally undervalued based on the Graham Number ($34.59) and Intrinsic Value ($29.77), yet it exhibits severe operational deterioration as evidenced by a weak Piotroski F-Score of 2/9. While the dividend is sustainable with a low payout ratio (33.74%), the combination of stagnant growth, bearish insider selling, and a 0/100 technical trend suggests a value trap scenario. The stock is trading at a discount, but the lack of internal health momentum offsets the valuation appeal.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HOMB vs JPM: Head-to-Head Comparison
This page compares Home BancShares, Inc. (HOMB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.